<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ipratropium (oral inhalation): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ipratropium (oral inhalation): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ipratropium (oral inhalation): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12231" href="/d/html/12231.html" rel="external">see "Ipratropium (oral inhalation): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="16003" href="/d/html/16003.html" rel="external">see "Ipratropium (oral inhalation): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F8120000"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Atrovent HFA</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869198"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AA-Ipravent;</li>
<li>Atrovent HFA;</li>
<li>PMS-Ipratropium;</li>
<li>TEVA-Ipratropium Bromide</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F8120010"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticholinergic Agent</li></ul></div>
<div class="block doa drugH1Div" id="F8120101"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5f85c008-c3a6-40c8-911a-69b590255e38">Asthma, acute exacerbation, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation, moderate to severe (off-label use):</b>
<b>Note:</b> May consider for treatment of moderate to severe exacerbations (eg, critically ill) in combination with a short-acting beta-adrenergic agonist. Nebulized therapy may be preferred in patients who have more severe symptoms or who cannot effectively use an inhaler (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Nebulization solution: <b>Oral inhalation:</b> 0.5 mg every 20 minutes for 3 doses, then hourly as needed for up to 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1','lexi-content-ref-NAEPP.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1','lexi-content-ref-NAEPP.2007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Metered-dose inhaler (17 mcg/actuation): <b>Oral inhalation: </b>4 to 8 inhalations with spacer every 20 minutes for 3 doses, then hourly as needed for up to 3 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1','lexi-content-ref-NAEPP.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1','lexi-content-ref-NAEPP.2007'])">Ref</a></span>). <b></b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d52d5bc2-9161-4b32-97a1-49c0d38ae6b0">Chronic obstructive pulmonary disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Acute exacerbation:</b></i>
<b>Note:</b> Although similar efficacy exists among formulations, some experts prefer nebulized therapy during severe chronic obstructive pulmonary disease (COPD) exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>). May be used in combination with an inhaled short-acting beta agonist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>For patients at home or office management:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Metered-dose inhaler (17 mcg/actuation): <b>Oral inhalation: </b>2 inhalations every 4 to 6 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Nebulization solution: <b>Oral inhalation: </b>0.5 mg every 6 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>For patients requiring emergency department or hospital-based care:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Nebulization solution: <b>Oral inhalation: </b>0.5 mg every 1 hour (up to 3 doses), then every 2 to 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Metered-dose inhaler (17 mcg/actuation): <b>Oral inhalation: </b>2 to 4 inhalations every 1 hour (up to 3 doses), then every 2 to 4 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stoller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stoller.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Intermittent symptom relief: </i>Note: </b>Use for intermittent symptoms on an as-needed basis rather than regularly scheduled maintenance therapy. Typically used in combination with inhaled short-acting beta agonist (SABA); combination therapy provides greater improvement in FEV<sub>1</sub> and symptoms over monotherapy SABA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler (17 mcg/actuation): <b>Oral inhalation: </b>2 inhalations 4 to 6 times daily as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1','lexi-content-ref-VaDod.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1','lexi-content-ref-VaDod.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization solution: <b>Oral inhalation: </b>0.5 mg every 4 to 8 hours as needed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ferguson.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ferguson.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Maintenance (alternative agent):</i> Note:</b> Depending on symptoms and exacerbation risk, preferred therapy is a single long-acting bronchodilator (long-acting beta agonist or long-acting muscarinic antagonist). In patients with more symptoms (eg, Group B), preferred therapy is dual long-acting bronchodilator therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler (17 mcg/actuation): <b>Oral inhalation: </b>2 inhalations every 6 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization solution: <b>Oral inhalation: </b>0.5 mg every 6 to 8 hours.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991127"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988453"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F8120102"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F8120100"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="16003" href="/d/html/16003.html" rel="external">see "Ipratropium (oral inhalation): Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85b2fb27-1a4a-40d6-b8b5-ab95601995d8">Asthma, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.2007'])">Ref</a></span>): <b>Note: </b>For moderate to severe exacerbations, ipratropium may be considered if poor response to initial short-acting beta-2 agonist (SABA) therapy during initial management in an acute care setting (eg, emergency department). Ipratropium has not been shown to provide further benefit (eg, after first 24 hours) once the patient is hospitalized (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-25080126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-25080126'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children:</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization: 0.25 to 0.5 mg (250 to 500 mcg) every 20 minutes for 1 hour (ie, 3 doses), then as needed; in trials, the usual reported dose is 0.25 mg (250 mcg) and reported interval range is every 1 to 8 hours typically with an increasing dosing interval as patient improves; some trials continued combination SABA/ipratropium therapy for duration of hospitalization (up to 49 hours) although trials have not demonstrated additional benefit with extended use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25080126']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25080126'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler: 4 to 8 puffs every 20 minutes as needed for up to 3 hours</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization: 0.5 mg (500 mcg) every 20 minutes for 3 doses, then as needed</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler: 8 puffs every 20 minutes as needed for up to 3 hours</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6eaf0529-96af-46d7-a15e-d8e3d1ed0ca2">Asthma, maintenance therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, maintenance therapy (nonacute):</b> Limited data available: <b>Note:</b> Evidence is lacking that ipratropium provides added benefit to beta-2 agonists in long-term control asthma therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.2007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.1','lexi-content-ref-NAEPP.2007'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;12 years:</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization: 0.25 to 0.5 mg (250 to 500 mcg) every 6 to 8 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler: 1 to 2 inhalations every 6 hours; not to exceed 12 inhalations/day</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Nebulization: 0.25 to 0.5 mg (250 to 500 mcg) every 6 hours</p>
<p style="text-indent:-2em;margin-left:6em;">Metered-dose inhaler: 2 to 3 inhalations every 6 hours; maximum daily dose: 12 inhalations/<b>day</b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5bd60265-6009-449c-a1b0-2e90a80f8a85">Bronchospasm associated with chronic pulmonary conditions</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchospasm associated with chronic pulmonary conditions:</b> Children ≥12 years and Adolescents: Nebulization: 0.5 mg (500 mcg, one unit-dose vial) 3 to 4 times daily with doses 6 to 8 hours apart</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9f72f9e8-f751-4d24-b11b-b8de4e6909c9">Bronchospasm, wheezing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bronchospasm, wheezing:</b> Limited data available; efficacy results variable: Infants: Nebulization: 0.125 to 0.25 mg (125 to 250 mcg) every 4 hours has been found helpful in some infants with chronic or recurrent wheezing, and some patients with bronchiolitis; however, most bronchiolitis data suggests ipratropium is not effective (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6457571','lexi-content-ref-2954510','lexi-content-ref-1437435','lexi-content-ref-6221700','lexi-content-ref-1533504']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6457571','lexi-content-ref-2954510','lexi-content-ref-1437435','lexi-content-ref-6221700','lexi-content-ref-1533504'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51113939"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (not studied); however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>
<div class="block dohp drugH1Div" id="F51113940"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (not studied); however, dosage adjustment unlikely necessary due to low systemic absorption.</p></div>
<div class="block adr drugH1Div" id="F8120048"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Respiratory: Bronchitis (10% to 23%), exacerbation of chronic obstructive pulmonary disease (8% to 23%), sinusitis (1% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (6% to 7%), dizziness (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dyspepsia (1% to 5%), nausea (4%), xerostomia (2% to 4%), dysgeusia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (2% to 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2% to 7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (7% to 8%), flu-like symptoms (4% to 8%), cough (&gt;3%), rhinitis (&gt;3%), upper respiratory tract infection (&gt;3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Accommodation disturbance, acute eye pain, anaphylaxis, angioedema, blurred vision, bronchospasm, conjunctival hyperemia, constipation, corneal edema, decreased gastrointestinal motility, diarrhea, dry throat, glaucoma, hypersensitivity reaction, hypotension, increased intraocular pressure, laryngospasm, mouth edema, mydriasis, nausea, palpitations, pharyngeal edema, pruritus, skin rash, stomatitis, tachycardia, throat irritation, urinary retention, urticaria, visual halos around lights, vomiting</p></div>
<div class="block coi drugH1Div" id="F8120045"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to ipratropium, atropine (and its derivatives), or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F8120046"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Paradoxical bronchospasm that may be life-threatening and may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response. If paradoxical bronchospasm occurs, discontinue ipratropium and institute alternative therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS effects: May cause dizziness and blurred vision; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm, oropharyngeal edema), including anaphylaxis, have been reported. Discontinue therapy immediately if patient develops an allergic reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Glaucoma: Use with caution in patients with narrow-angle glaucoma; may increase intraocular pressure.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/bladder neck obstruction: Use with caution in patients with prostatic hyperplasia or bladder neck obstruction; may cause urinary retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response. Only use in acute exacerbations of asthma in conjunction with short-acting beta-adrenergic agonists for acute episodes (NAEPP 2007).</p></div>
<div class="block dosfc drugH1Div" id="F21003347"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Atrovent HFA 12.9 g canister contains 200 inhalations.</p></div>
<div class="block foc drugH1Div" id="F8120136"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Inhalation, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atrovent HFA: 17 mcg/actuation (12.9 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation, as bromide: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.02% (2.5 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Inhalation, as bromide [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.02% (2.5 mL)</p></div>
<div class="block geq drugH1Div" id="F8120003"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F8120138"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol solution</b> (Atrovent HFA Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">17 mcg/ACT (per gram): $43.91</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Ipratropium Bromide Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.02% (per mL): $0.14 - $0.89</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869199"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atrovent HFA: 20 mcg/actuation (1 ea) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Nebulization Solution, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.125 mg/mL (2 mL); 0.25 mg/mL (0.5 mL, 1 mL, 2 mL, 20 mL)</p></div>
<div class="block adm drugH1Div" id="F8120124"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">For oral inhalation; avoid spraying in eyes.</p>
<p style="text-indent:-2em;margin-left:2em;">Metered-dose inhaler: Prior to initial use, prime inhaler by releasing 2 test sprays into the air; inhaler does not require shaking. If the inhaler has not been used for &gt;3 days, reprime. Wash mouthpiece once a week for 30 seconds in warm water only and let air dry. Discard inhaler once dose indicator displays “0.”</p>
<p style="text-indent:-2em;margin-left:2em;">Nebulization solution: Remove unit dose vial from foil pouch and squeeze contents into nebulizer reservoir; connect nebulizer to compressor. Breathe deeply and evenly until all medication has been inhaled; inhalation time is about 5 to 15 minutes. Clean nebulizer after use. Compatibility with other medications (eg, albuterol, budesonide) in nebulizer has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20101066','lexi-content-ref-24172851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20101066','lexi-content-ref-24172851'])">Ref</a></span>); also refer to institution-specific policies.</p></div>
<div class="block admp drugH1Div" id="F52614361"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Inhalation:</p>
<p style="text-indent:-2em;margin-left:2em;">Nebulization: May be administered with or without dilution in NS; use of a nebulizer with a mouth piece, rather than a face mask, may be preferred to prevent contact with eyes. Compatibility with other medications (eg, albuterol, budesonide) in nebulizer has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20101066','lexi-content-ref-24172851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20101066','lexi-content-ref-24172851'])">Ref</a></span>); also refer to institution-specific policies.</p>
<p style="text-indent:-2em;margin-left:2em;">Oral Inhalation (metered-dose inhaler): Atrovent HFA: Prior to initial use, prime inhaler by releasing 2 test sprays into the air. If the inhaler has not been used for &gt;3 days, reprime. Avoid spraying into the eyes. Use spacer device in children &lt;8 years; use spacer device and face mask for children ≤4 years.</p></div>
<div class="block use drugH1Div" id="F8120017"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Chronic obstructive pulmonary disease:</b> Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema</p></div>
<div class="block off-label drugH1Div" id="F27657628"><span class="drugH1">Use: Off-Label: Adult</span><p>Asthma, acute exacerbation, moderate to severe</p></div>
<div class="block mst drugH1Div" id="F8117604"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Atrovent may be confused with Alupent, Serevent</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ipratropium may be confused with tiotropium</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299541"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F8120053"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: Ipratropium (Oral Inhalation) may enhance the anticholinergic effect of Anticholinergic Agents. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrronium (Topical): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Ipratropium (Oral Inhalation) may diminish the therapeutic effect of Methacholine.  Management: Hold ipratropium for 12 hours before methacholine use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Agonists. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate.  Management:  Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium citrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Revefenacin: Anticholinergic Agents may enhance the anticholinergic effect of Revefenacin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Anticholinergic Agents may diminish the therapeutic effect of Rivastigmine. Rivastigmine may diminish the therapeutic effect of Anticholinergic Agents.  Management: Use of rivastigmine with an anticholinergic agent is not recommended unless clinically necessary. If the combination is necessary, monitor for reduced anticholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F8120043"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Systemic exposure following inhalation is negligible; maternal use is not expected to result in fetal exposure. Data related to ipratropium for the treatment of asthma in pregnancy are limited. Based on available information, an increased risk of adverse maternal or fetal outcomes has not been observed following use during pregnancy.</p>
<p style="text-indent:0em;margin-top:2em;">Uncontrolled asthma is associated with adverse events on pregnancy (increased risk of perinatal mortality, preeclampsia, preterm birth, low birth weight infants, cesarean delivery, and the development of gestational diabetes). Poorly controlled asthma or asthma exacerbations may have a greater fetal/maternal risk than what is associated with appropriately used asthma medications. Maternal treatment improves pregnancy outcomes by reducing the risk of some adverse events (eg, preterm birth, gestational diabetes). Maternal asthma symptoms should be monitored monthly during pregnancy (ERS/TSANZ [Middleton 2020]; GINA 2023).</p></div>
<div class="block brc drugH1Div" id="F20679322"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if ipratropium is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Systemic exposure following inhalation is negligible which would limit excretion into breast milk. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F50020777"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; signs/symptoms of glaucoma; hypersensitivity reactions; urinary retention</p></div>
<div class="block pha drugH1Div" id="F8120084"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Blocks the action of acetylcholine at parasympathetic sites in bronchial smooth muscle causing bronchodilation; local application to nasal mucosa inhibits serous and seromucous gland secretions.</p></div>
<div class="block phk drugH1Div" id="F8120086"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Bronchodilation: Within 15 minutes</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: 1 to 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Metered-dose inhaler: 2 to 4 hours; Nebulization solution: 4 to 5 hours, up to 7 to 8 hours in some patients</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Not readily absorbed into the systemic circulation from the surface of the lung or from the GI tract; ~7% absorbed after nebulization of a 2 mg dose</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: 15% of dose reaches lower airways</p>
<p style="text-indent:-2em;margin-left:2em;">Protein Binding: ≤9%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Partially metabolized to inactive ester hydrolysis products</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961981"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aerotrop | Atrovent | Atrovent hfa | Iprabron</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ipramid | Iprex</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Atronase | Atrovent</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Atrovent n</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Aerotrop | Atrovent | Influmix | Iprasynt hfa</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aspromio | Atrovent | Atrovent hfa | Biovent | Bromuro de ipratropio | Ciplatropiun | Ipramar | Iprasynt | Ipratropio bromuro | Plamune</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n | Iprabronch | Ipratropiumbromid hexal | Ipravent</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Aerotrop | Atrovent | I Patrimul | Ipratum | Tropium</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Aspromio | Atrovent | Atrovent hfa | Ipratropio</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Atroaldo | Atrovent | Ipratropio bromuro cipla | Ipratropio bromuro Kern Pharma</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent eco</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Inhalvent | Ipratropium | Ipravent | Ipravent cfc</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Broncovent</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent n</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n | Ipravent</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Aerovent | Atrovent</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Ipramist | Ipratop | Ipravent</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Ipravent</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Atem | Rinovagos</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Atrovent hfa</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Atem | Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Atronase | Atrovent</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Bromuro de ipratropio | Ipralong | Iprasynt | Ipratropio | Protaisol</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Ipracip | Ipravent</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent(es) | Ipratropiumbromide Sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Aerotrop | Atrovent | Atrovent hfa | Bromuro de ipratropio | Flavuril | Ipramar | Iprapharm | Ipratrolab | Ipratum</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Atem | Estravent | Ipravent | Optra | Optra HFA | Trupium</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Atrodil | Atrovent | Atrovent n</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent hfa | Ipratropium br</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent pa | Brometo de ipratropio bluepharma</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Aerotrop | Anasmal | Atrovent hfa | Bromovent</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Atrovent MDI | Atrovent UDV | Ipravent</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Ipravent</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Atrovent n | Ipratropium aeronativ | Ipratroppem | Ipravent</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Ipratropiumbromid Ebb | Ipravent</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Iprovent</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Atroaldo | Atrovent</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Ipracort</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Atrovent</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Atrovent | Ipratropium inteli | Ipravent</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Aerotrop | Atrovent | Estravent</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Alovent | Atroaldo | Bromuro de ipratropio | Ipatrixair | Iprasynt | Ipratropio bromuro</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Atronase | Atrovent | Ipvent</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-AtroventHFA.1">
<a name="AtroventHFA.1"></a>Atrovent HFA (ipratropium) [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2146910">
<a name="2146910"></a>Brundage KL Mohsini KG, Froese AB, et al. Bronchodilator response to ipratropium bromide in infants with bronchopulmonary dysplasia. <i>Am Rev Respir Dis</i>. 1990;142:1137-1142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/2146910/pubmed" id="2146910" target="_blank">2146910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20101066">
<a name="20101066"></a>Burchett DK, Darko W, Zahra J, Noviasky J, Probst L, Smith A. Mixing and compatibility guide for commonly used aerosolized medications. <i>Am J Health Syst Pharm</i>. 2010;67(3):227-230. doi:10.2146/ajhp080261<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/20101066/pubmed" id="20101066" target="_blank">20101066</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Dweik.1">
<a name="Dweik.1"></a>Dweik RA. Role of muscarinic antagonist therapy in COPD. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 22, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.1">
<a name="Fanta.1"></a>Fanta CH, Cahill KN. Acute exacerbations of asthma in adults: Emergency department and inpatient management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377401">
<a name="17377401"></a>Fayon M, Tayara N, Germain C, et al. Efficacy and tolerance of high-dose inhaled ipratropium bromide vs. terbutaline in intubated premature human neonates. <i>Neonatology</i>. 2007;91:167-173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/17377401/pubmed" id="17377401" target="_blank">17377401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ferguson.1">
<a name="Ferguson.1"></a>Ferguson GT. Stable COPD: initial pharmacologic management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.1">
<a name="GINA.1"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Updated 2019. Accessed September 23, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2021">
<a name="GINA.2021"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23966133">
<a name="23966133"></a>Griffiths B, Ducharme FM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. <i>Cochrane Database Syst Rev</i>. 2013;8:CD000060. doi:10.1002/14651858.CD000060.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/23966133/pubmed" id="23966133" target="_blank">23966133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6230059">
<a name="6230059"></a>Henry RI, Hiller EG, Milner AD, et al, “Nebulized Ipratropium Bromide and Sodium Cromoglycate in the First 2 Years of Life,” <i>Arch Dis Child</i>, 1984, 59(1):54-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/6230059/pubmed" id="6230059" target="_blank">6230059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6457571">
<a name="6457571"></a>Hodges IGC, Groggins RC, Milner AD, et al. Bronchodilator effect of inhaled ipratropium bromide in wheezy toddlers. <i>Arch Dis Child</i>. 1981;56(9):729-732.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/6457571/pubmed" id="6457571" target="_blank">6457571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2962074">
<a name="2962074"></a>Hughes DT, “The Use of Anticholinergic Drugs in Nocturnal Asthma,” <i>Postgrad Med J</i>, 1987, 63(Suppl 1):47-51.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/2962074/pubmed" id="2962074" target="_blank">2962074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mylan.1">
<a name="Mylan.1"></a>Ipratropium bromide inhalation solution [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; May 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24172851">
<a name="24172851"></a>Kamin W, Erdnüss F, Krämer I. Inhalation solutions--which ones may be mixed? Physico-chemical compatibility of drug solutions in nebulizers--update 2013. <i>J Cyst Fibros</i>. 2014;13(3):243-250. doi:10.1016/j.jcf.2013.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/24172851/pubmed" id="24172851" target="_blank">24172851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8198418">
<a name="8198418"></a>Lee H, Arnon S, Silverman M. Bronchodilator aerosol administered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome. <i>Archives of Disease in Childhood</i>. 1994;70:218-222.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/8198418/pubmed" id="8198418" target="_blank">8198418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6461943">
<a name="6461943"></a>Mann NP and Hiller RG, “Ipratropium Bromide in Children With Asthma,” <i>Thorax</i>, 1982, 37(1):72-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/6461943/pubmed" id="6461943" target="_blank">6461943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31699837">
<a name="31699837"></a>Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases. <i>Eur Respir J</i>. 2020;55(2):1901208. doi:10.1183/13993003.01208-2019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/31699837/pubmed" id="31699837" target="_blank">31699837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.2007">
<a name="NAEPP.2007"></a>National Asthma Education and Prevention Program (NAEPP). Expert Panel Review Report 3: Guidelines for the diagnosis and management of asthma. National Heart, Blood, and Lung Institute. <a href="https://www.nhlbi.nih.gov/sites/default/files/media/docs/EPR-3_Asthma_Full_Report_2007.pdf" target="_blank">https://www.nhlbi.nih.gov/sites/default/files/media/docs/EPR-3_Asthma_Full_Report_2007.pdf</a>. Published 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8521214">
<a name="8521214"></a>Osmond MH and Klassen TP, “Efficacy of Ipratropium Bromide in Acute Childhood Asthma: A Meta-Analysis,” <i>Acad Emerg Med</i>, 1995, 2(7):651-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/8521214/pubmed" id="8521214" target="_blank">8521214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2954510">
<a name="2954510"></a>Prendiville A, Green S, Silverman M. Ipratropium bromide and airways function in wheezy infants. <i>Archives of Disease in Childhood</i>. 1987;62:397-400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/2954510/pubmed" id="2954510" target="_blank">2954510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16055613">
<a name="16055613"></a>Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. <i>Thorax</i>. 2005;60(9):740-746.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/16055613/pubmed" id="16055613" target="_blank">16055613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10852758">
<a name="10852758"></a>Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. <i>Am J Respir Crit Care Med</i>. 2000;161(6):1862-1868.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/10852758/pubmed" id="10852758" target="_blank">10852758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7699549">
<a name="7699549"></a>Schuh S, Johnson DW, Callahan S, et al, "Efficacy of Frequent Nebulized Ipratropium Bromide Added to Frequent High-Dose Albuterol Therapy in Severe Childhood Asthma," <i>J Pediatr</i>, 1995, 126(4):639-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/7699549/pubmed" id="7699549" target="_blank">7699549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1437435">
<a name="1437435"></a>Schuh S, Johnson DW, Canny G, et al, “Efficacy of Adding Nebulized Ipratropium Bromide to Nebulized Albuterol Therapy in Acute Bronchiolitis,” <i>Pediatrics</i>, 1992, 90(6):920-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/1437435/pubmed" id="1437435" target="_blank">1437435</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6221700">
<a name="6221700"></a>Stokes GM, Milner AD, Hodges IGC, et al. Nebulized therapy in acute severe bronchitis in infancy. <i>Archives of Disease In Childhood</i>. 1983;58:279-282.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/6221700/pubmed" id="6221700" target="_blank">6221700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stoller.1">
<a name="Stoller.1"></a>Stoller JK. COPD exacerbations: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 14, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VaDod.1">
<a name="VaDod.1"></a>US Department of Veterans Affairs (VA/DoD). VA/Dod clinical practice guidelines: management of chronic obstructive pulmonary disease. <a href="https://www.healthquality.va.gov/guidelines/cd/copd/" target="_blank">https://www.healthquality.va.gov/guidelines/cd/copd/</a>. Updated 2021. Accessed September 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25080126">
<a name="25080126"></a>Vézina K, Chauhan BF, Ducharme FM. Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. <i>Cochrane Database Syst Rev</i>. 2014(7):CD010283.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/25080126/pubmed" id="25080126" target="_blank">25080126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1533504">
<a name="1533504"></a>Wang EE, Milner R, Allen U, et al, "Bronchodilators for Treatment of Mild Bronchiolitis: A Factorial Randomised Trial," <i>Arch Dis Child</i>, 1992, 67(3):289-93.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/1533504/pubmed" id="1533504" target="_blank">1533504</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2956405">
<a name="2956405"></a>Wilkie RA and Bryan MH, “Effect of Bronchodilators on Airway Resistance in Ventilator-dependent Neonates With Chronic Lung Disease,” <i>J Pediatr</i>, 1987, 111(2):278-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipratropium-oral-inhalation-drug-information/abstract-text/2956405/pubmed" id="2956405" target="_blank">2956405</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9148 Version 343.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
